What explains the concordance between MB-FUS-enriched plasma cfDNA and disease trajectories?

neuro-oncology open
Open a bounty challenge Fund this gap and accept submissions. SPEC-033.
Composite
—
Novelty
—
Mechanistic
—
Druggability
—
Priority
75%
Importance
78%
Tractability
70%
Market price
50%

Description

The abstract mentions patient-specific disease courses were concordant with trajectories of MB-FUS-enriched plasma cell-free DNA but provides no mechanistic explanation. Understanding this relationship could reveal biomarkers for treatment response or disease monitoring.

Gap type: unexplained_observation Source paper: Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial. (2025, The Lancet. Oncology, PMID:41308679)